Related Experiment Video
Updated: Jun 12, 2025
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Beyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management
Amirabbas Rostami1, Ehsan Ranjbar2, Somayeh Amiri3
1Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract:
In addressing the challenges of lung cancer, attention has increasingly turned to molecular diagnostics and targeted therapies, with nucleolin (NCL) assuming a pivotal role, especially in non-small cell lung cancer. The aberrant activity and cellular distribution of NCL act as crucial biomarkers for early detection and treatment monitoring, showing a strong correlation with disease progression and patient prognosis. Elevated NCL levels signal advanced disease and poorer outcomes, underscoring its significance in evaluating disease severity and therapeutic response. Strategies targeting the molecular interactions of NCL have spurred innovative approaches to inhibit tumour growth, overcome drug resistance and improve treatment efficacy. These advancements are paving the way for personalized therapies tailored to the unique molecular profiles of patients' tumours. Consequently, NCL stands at the forefront of lung cancer management, symbolizing the move towards more precise and individualized oncology care, and marking substantial progress in therapeutic development.
Insights
Nucleolin (NCL) is a key biomarker in lung cancer diagnostics and therapy. Targeting NCL offers new avenues for personalized non-small cell lung cancer treatments and improved patient outcomes.
Area of Science:
- Oncology
- Molecular Diagnostics
- Biomarkers
Background:
- Lung cancer management increasingly focuses on molecular diagnostics and targeted therapies.
- Nucleolin (NCL) plays a critical role, particularly in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To highlight the significance of nucleolin (NCL) as a biomarker in lung cancer.
- To explore NCL-targeting strategies for improved therapeutic efficacy.
Main Methods:
- Analysis of NCL's role in disease progression and prognosis.
- Review of NCL-targeting strategies for cancer therapy.
Main Results:
- Aberrant NCL activity and distribution are crucial biomarkers for early detection and monitoring.
- Elevated NCL levels correlate with advanced disease and poorer patient prognosis.
- NCL targeting shows promise in inhibiting tumor growth and overcoming drug resistance.
Conclusions:
- Nucleolin (NCL) is central to advancing lung cancer management.
- NCL represents a significant step towards personalized oncology and improved therapeutic development.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
